Singapore Institute of Advanced Medicine Holdings Ltd
Singapore Institute of Advanced Medicine Holdings Ltd ("Sam" or the "Company") is offering 114m new shares comprising 4.415m Public Offer Shares and 109.585m Placement Shares at $0.23 each for a listing on Catalist. The Company aims to raise $26.2m and the majority of the proceeds will be used to repay debt and the balance for working capital. The market cap based on the IPO price is $231.8m and the offer will close on 14 Feb at 12 noon and starts trading on 16 Feb 2024 at 9am. Principal Business SAM is a healthcare service provider using advanced technology for early and accurate diagnosis to detect and treat cancer, neurodegenerative and cardiovascular diseases. SAM has strategic collaborations with public and private institutions for research and clinical work. SAM's goal is to create a comprehensive one-stop ambulatory cancer centre to undertake the challenges to fight cancer and is one of the first to adopt proto beam therapy treatment in Singapore. Fi
Comments
Do you think the returned funds for those who are unsuccessful from GLP will be on time for the application for MIT ?
The timing is too close and certainly not comfortable !!!
Its billed as a china play but last I check, only 20% of its properties are in China.
Firstly, this is not a reit. There has been no history of dividend being paid out as all profits are being reinvested and there probably won't be in the near future. Any gains investors expect should come from capital gains.
Secondly,from the prospectus, 227 out of its total 296 completed properties are in china. Hence, china properties accounts for 77% of GLP completed properties.
This stock is hot due to factors such as the huge growth potential in china, good track record from its management, good backers such as GIC and many more.